---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-094155"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:25:14.882064+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cadrenal raises $4.7M via warrant exercise; issues new warrants for additional shares

## Summary
- Exercised 285,715 existing warrants at reduced price of $16.50/share, generating ~$4.7M gross proceeds.
- Issued new Series A-1 and A-2 warrants each to purchase 285,715 shares at $16.50/share as inducement.
- Net proceeds to fund pivotal Phase 3 trial of tecarfarin and partnering activities.
- H.C. Wainwright & Co. served as placement agent; receives 7% cash fee and 18,571 placement agent warrants.
- New Series A-1 warrants expire in 5 years; Series A-2 expire 18 months after resale registration effective.

## SEC filing metadata
- accession: 0001213900-24-094155
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024094155/0001213900-24-094155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024094155/ea0219768-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-094155
- JSON: https://secwatch.observer/filing/0001213900-24-094155.json
- Plain text: https://secwatch.observer/filing/0001213900-24-094155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.